Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
CAMP vs CBIO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CBIO Captures Overall Composite Edge (42.4 HOLD vs 43.9 HOLD), While CAMP Leads 4–1 on Growth & Valuation Pillars
CBIO Overall Winner
6-Pillar Tally: CAMP 4 – 1 CBIO (1 Tie)
Matrix Metrics: CAMP 4 – 3 CBIO
As of Nov 17, 2026, Crescent Biopharma, Inc. (CBIO) captures the overall head-to-head institutional edge over CAMP4 Therapeutics Corporation (CAMP) on higher Unified Composite conviction (42.4/100 HOLD vs. 43.9/100 HOLD) after splitting the core matrix 3–4 (led by Options & Positioning), while CAMP wins 4–1 across the 6-pillar growth and valuation breakdown. CAMP trades at $3.95 (N/M Forward P/E, -991.8% operating margin) versus CBIO at $13.30 (N/M Forward P/E, -1228.4% operating margin).
- Composite vs. Pillar Nuance: While CAMP currently prints a higher short-term Unified Composite Score (43.9/100 HOLD vs. CBIO 42.4/100 HOLD), CBIO captures the overall institutional head-to-head verdict (3–4 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (-1228.4% vs. -991.8% operating margin) and revenue trajectory (+0.0% vs. +138.9% YoY).
- Technical & Structure Timing Caution: CAMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.9); meanwhile CBIO is in a Breakdown options structure phase (RSI 45.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About CAMP vs CBIO
CAMP
CAMP4 Therapeutics Corporation Common Stock
$3.95
+2.33% 1D
Market Cap
$238.5M
TTM Revenue
$5.3M
Forward P/E
N/M
Beta / 30D Vol
1.34β · 94% Vol
Unified Composite Score
43.9
HOLD
Tech 34.0
Fund 40.0
Flow 50.0
Mom 40.0
Weinstein Technical Phase
Neutral · Hold
CBIO
Head-to-Head Winner
Crescent Biopharma, Inc. Common Stock
$13.30
-1.48% 1D
Market Cap
$591.3M
TTM Revenue
$15M
Forward P/E
N/M
Beta / 30D Vol
1.38β · 58% Vol
Unified Composite Score
42.4
HOLD
Tech 36.0
Fund 51.0
Flow 65.0
Mom 50.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (CAMP 4 – 1 CBIO)
1. Valuation Multiples
CAMP
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
26.6x
28.1x
2. Growth & Scale
CAMP
Revenue Growth (YoY)
+138.9%
+0.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$5.3M
$15M
Market Cap
$238.5M
$591.3M
3. Profitability & Quality
CAMP
Gross Margin
N/A
100.0%
Operating Margin
-991.8%
-1228.4%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-146.1%
-160.8%
4. Balance Sheet & Cash Flow
CAMP
Cash Generation (TTM)
-$26M
-$154M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$97M Net Cash
$170M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
CBIO
Options Structure Phase
UNCLASSIFIED
BREAKDOWN
Current IV / %ile
N/A (N/A)
127.8% (10th %ile)
Put/Call OI Skew
N/A
1.07x (Balanced)
OBV Trend / Tech Phase
NEUTRAL · Neutral
NEUTRAL · Neutral
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: CAMP (4) vs CBIO (3)| Institutional Metric | CAMP | CBIO | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $238.5M | $591.3M | CBIO | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +138.9% | +0.0% | CAMP | |
| Operating Margin (TTM) | -991.8% | -1228.4% | CAMP | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -146.1% | -160.8% | CAMP | |
| 52-Week Range Position | 22% ($3–$8) | 24% ($9–$27) | CBIO | |
| Beta / 30D Volatility | 1.34β · 94% Vol | 1.38β · 58% Vol | CBIO | |
| Unified Institutional Score | 43.9 / 100 (HOLD) | 42.4 / 100 (HOLD) | CAMP | |
| Trailing 12M Revenue (USD) | $5.3M | $15M | Scale | |
| Gross Profit Margin (TTM) | N/A | 100.0% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 26.6x EV/Rev | N/M PEG · 28.1x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$26M ($97M Net Cash) | -$154M ($170M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
CAMP +18.19 pp
3M Horizon
CAMP +8.16 pp
6M Horizon
CAMP +23.21 pp
1Y Horizon
CBIO +5.81 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CAMP Revenue | CBIO Revenue | CAMP Op. Margin | CBIO Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2015 | N/A | $20M | N/A | -63.7% | CBIO |
| FY2016 | N/A | $0M | N/A | -172505.3% | CBIO |
| FY2020 | N/A | $10M | N/A | -506.8% | CBIO |
| FY2021 | N/A | $0M | N/A | -5470.7% | CBIO |
| FY2022 | N/A | $0M | N/A | -63204.4% | CBIO |
| FY2023 | $0M | $0M | -14822.6% | -392752.9% | CAMP |
| FY2024 | $0M | N/A | -8142.3% | N/A | CAMP |
| FY2025 | $0M | $10M | -1502.4% | -1407.5% | CBIO |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
CAMP
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact CAMP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
CBIO
BREAKDOWN
Current IV
127.8%
IV Percentile
10th %ile
Put/Call OI Skew
1.07x (Balanced)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact CBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
CAMP Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
CBIO Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ CAMP vs CBIO Key Questions & Quantitative Answers
As of Nov 17, 2026, Crescent Biopharma, Inc. (CBIO) captures the overall head-to-head institutional edge over CAMP4 Therapeutics Corporation (CAMP) on higher Unified Composite conviction (42.4/100 HOLD vs. 43.9/100 HOLD) after splitting the core matrix 3–4 (led by Options & Positioning), while CAMP wins 4–1 across the 6-pillar growth and valuation breakdown. CAMP trades at $3.95 (N/M Forward P/E, -991.8% operating margin) versus CBIO at $13.30 (N/M Forward P/E, -1228.4% operating margin). Composite vs. Pillar Nuance: While CAMP currently prints a higher short-term Unified Composite Score (43.9/100 HOLD vs. CBIO 42.4/100 HOLD), CBIO captures the overall institutional head-to-head verdict (3–4 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (-1228.4% vs. -991.8% operating margin) and revenue trajectory (+0.0% vs. +138.9% YoY). Technical & Structure Timing Caution: CAMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.9); meanwhile CBIO is in a Breakdown options structure phase (RSI 45.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CAMP leads the Growth & Scale pillar: CAMP posts +138.9% YoY revenue growth and +0.0% YoY earnings growth on $5.3M TTM revenue (N/A gross margin, -991.8% operating margin), compared with CBIO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $15M TTM revenue (100.0% gross margin, -1228.4% operating margin). Across the 8-period historical trajectory (FY2015 to FY2025), CAMP cumulative revenue shifted N/A while CBIO shifted -50.0%. In operating R&D and SG&A reinvestment, CAMP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CBIO.
CAMP screens cheaper on headline valuation multiples. CAMP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 26.6x EV/Revenue (unreported FCF margin), whereas CBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 28.1x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CAMP (-146.1% ROE) versus CBIO (-160.8% ROE) capital efficiency.
In options market volatility and institutional positioning, CAMP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.34β · 94% Vol realized risk). By comparison, CBIO carries 127.8% implied volatility (10th %ile, Compressed (<25th %ile)), a 1.07x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.38β · 58% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
CBIO vs CAMP · Reverse Pair
CAMP vs HLIT
· Sector Peer
CAMP vs ADTN
· Sector Peer
CAMP vs DGII
· Sector Peer
CBIO vs BNTC
· Sector Peer
CBIO vs AKTX
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem